What is Antabio?
Antabio is dedicated to developing highly differentiated antibacterial treatments targeting critical priority pathogens identified by the CDC and WHO. The company's primary focus is on life-threatening respiratory infections, including carbapenem-resistant nosocomial pneumonia and chronic pulmonary diseases. Its lead program, MEM-ANT3310, is specifically designed to combat hospital-acquired infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Enterobacterales (CRE), addressing a significant unmet medical need in critical care settings. The company's strategic approach involves creating novel therapies to overcome the limitations of existing antibiotics.
How much funding has Antabio raised?
Antabio has raised a total of $38.3M across 3 funding rounds:
Share Placement
$2.8M
Series A
$8.6M
Series B
$26.9M
Share Placement (2017): $2.8M with participation from Carb-X
Series A (2017): $8.6M led by iXO Private Equity, IRDI SORIDEC Gestion, and Galia Gestion
Series B (2023): $26.9M supported by The AMR Action Fund and BNP Paribas Développement
Key Investors in Antabio
The AMR Action Fund
The AMR Action Fund is a venture capital fund dedicated to investing in companies developing novel antibiotics to combat antimicrobial resistance. They aim to ensure a sustainable pipeline of new treatments for patients with life-threatening infections.
iXO Private Equity
iXO Private Equity is an independent French private equity firm focused on small and mid-cap investments, primarily in the Grand Sud region of France, managing approximately 1 billion euros.
Carb-X
CARB-X is a global non-profit accelerator that funds the development of new antibiotics and other life-saving products to combat dangerous drug-resistant bacteria, focusing on early-stage innovation.
What's next for Antabio?
With the recent major strategic investment, Antabio is well-positioned to advance its pipeline and accelerate the development of its novel antibacterial therapies. The substantial capital infusion is expected to fuel clinical trials, expand research and development efforts, and potentially scale up manufacturing capabilities. This funding signifies a crucial step in Antabio's journey to bring life-saving treatments to patients battling drug-resistant infections, reinforcing its commitment to tackling the global AMR crisis. The company's trajectory suggests a focus on achieving key clinical milestones and securing regulatory approvals in the near future.
See full Antabio company page
